Trial Profile
The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure (NYHA II): a Randomized Comparator-Controlled Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2012 Planned end date changed from 1 Mar 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 19 Apr 2011 Planned End Date changed from 1 Jun 2011 to 1 Mar 2012, as reported by ClinicalTrials.gov.